Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P48553
UPID:
TPC10_HUMAN
Alternative names:
Epilepsy holoprosencephaly candidate 1 protein; Protein GT334; Trafficking protein particle complex subunit TMEM1; Transport protein particle subunit TMEM1
Alternative UPACC:
P48553; Q3MIR2; Q86SI7; Q9UMD4; Q9Y4L3
Background:
Trafficking protein particle complex subunit 10, also known as Epilepsy holoprosencephaly candidate 1 protein, Protein GT334, Trafficking protein particle complex subunit TMEM1, and Transport protein particle subunit TMEM1, plays a pivotal role in the TRAPP II complex. This complex is essential for late Golgi trafficking, acting as a membrane tether in cellular processes.
Therapeutic significance:
The protein is linked to a neurodevelopmental disorder characterized by microcephaly, short stature, and speech delay, suggesting its critical role in brain development. Understanding the role of Trafficking protein particle complex subunit 10 could open doors to potential therapeutic strategies for treating such neurodevelopmental disorders.